Janney Montgomery Scott LLC Has $1.47 Million Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Janney Montgomery Scott LLC increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 30.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,487 shares of the company’s stock after buying an additional 15,332 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Cellebrite DI were worth $1,465,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of CLBT. JPMorgan Chase & Co. boosted its holdings in shares of Cellebrite DI by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after acquiring an additional 75,092 shares during the period. Telemark Asset Management LLC bought a new position in shares of Cellebrite DI in the third quarter worth about $6,736,000. Two Sigma Advisers LP lifted its stake in Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after purchasing an additional 120,000 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Cellebrite DI by 65.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after acquiring an additional 62,320 shares in the last quarter. Finally, State Street Corp grew its position in Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock worth $7,472,000 after acquiring an additional 30,052 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on CLBT shares. Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Needham & Company LLC increased their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI currently has a consensus rating of “Buy” and an average price target of $21.57.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $24.67 on Tuesday. Cellebrite DI Ltd. has a fifty-two week low of $8.91 and a fifty-two week high of $24.89. The company’s 50-day moving average is $21.77 and its 200 day moving average is $18.46. The company has a market capitalization of $5.08 billion, a P/E ratio of -15.92, a price-to-earnings-growth ratio of 3.55 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Cellebrite DI’s revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.09 earnings per share. As a group, research analysts predict that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.